logo
Share SHARE
FONT-SIZE Plus   Neg

Lilly: Phase 3 MONARCH 2 Breast Cancer Study Of Abemaciclib Met Primary Endpoint

Eli Lilly and Co. (LLY) announced Monday that its MONARCH 2 breast cancer Study trial of abemaciclib met the primary endpoint of progression-free survival. Abemaciclib, in combination with fulvestrant, was superior to fulvestrant plus placebo in patients with HR+, HER2- advanced breast cancer, the company noted.

The Phase 3 study evaluated abemaciclib, a cyclin-dependent kinase or CDK 4 and CDK 6 inhibitor, in combination with fulvestrant in women with hormone-receptor-positive or HR+, human epidermal growth factor receptor 2-negative, advanced breast cancer who have relapsed or progressed after endocrine therapy.

The results demonstrated the addition of abemaciclib to fulvestrant resulted in a statistically significant improvement in PFS, when compared to the control arm of placebo plus fulvestrant. Detailed efficacy and safety results will be presented at an upcoming medical meeting.

The global Phase 3, double-blind study was designed to evaluate the efficacy and safety of abemaciclib, in combination with fulvestrant, in patients with advanced breast cancer.

The most common adverse events observed were diarrhea, neutropenia, nausea and fatigue, and were consistent with the previous studies of abemaciclib.

Lilly intends to submit a new drug application or NDA for single-agent abemaciclib in the second quarter of 2017, based on the MONARCH 1 study.

Lilly plans to submit an additional application for MONARCH 2 in the third quarter of this year.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Two major hospitals Ascension Health and Providence St. Joseph Health are in discussion for merger to create one of the largest hospital chain, reported Wall Street Journal. The combination is expected to have 191 hospitals with an annual revenue of around $45 billion. The new entity would dethrone America's largest hospital operator Hospital Corporation of America that owns 177 hospitals and reve Uber has mistakenly charged a customer in Toronto an astounding C$18,518.50 for a five-mile, 21-minute ride. In U.S. dollar terms, the amount would be more than $14,400. The five-mile ride should have only cost between C$12 and C$16. French baby formula maker Lactalis has issued a major international product recall over fears of salmonella contamination. French health authorities have ordered the dairy company to stop selling hundreds of products worldwide, after 26 infants fell ill with salmonella poisoning in France. Salmonella infections can be life-threatening mainly for young children.
comments powered by Disqus
Follow RTT